SILVER SPRING, Md.—An epidemiologist with the Food and Drug Administration on Monday laid out why the anti-inflammatory pain drug naproxen may carry lower cardiovascular risks than comparable drugs.. The epidemiologist, Dr. Andrew D. Mosholder, made the remarks at a pivotal FDA advisory committee meeting here to determine whether the agency will let drug makers differentiate the pain drugs' labels based on their safety risks. Aleve is Bayer AG's brand name for naproxen.